Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, randomized, phase II clinical trial, which aims to
evaluate the effectiveness and safety of gefitinib versus combination of gefitinib and
doublet chemotherapy or apatinib in advanced non-small cell lung cancer (NSCLC) patients with
epidermal growth factor receptor (EGFR) activating mutation (exon 19 deletion or exon 21
L858R point mutation), accompanied with Bim deletion or low activating EGFR mutation
abundance.